VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 101.2% in July

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 538,529 shares, an increase of 101.2% from the July 15th total of 267,687 shares. Currently, 6.7% of the company’s stock are short sold. Based on an average trading volume of 308,439 shares, the days-to-cover ratio is presently 1.7 days.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Armistice Capital LLC grew its position in shares of VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares during the last quarter. Geode Capital Management LLC lifted its position in VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares during the last quarter. Citadel Advisors LLC boosted its stake in VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. Squarepoint Ops LLC acquired a new position in VolitionRX in the fourth quarter valued at $34,000. Finally, Jane Street Group LLC purchased a new position in shares of VolitionRX during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

Analyst Ratings Changes

VNRX has been the subject of several analyst reports. Benchmark reiterated a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. Finally, Citigroup downgraded shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.00.

VolitionRX Stock Performance

Shares of NYSEAMERICAN VNRX opened at $0.54 on Monday. The stock’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $2.72. The firm has a market capitalization of $4.64 million, a PE ratio of -0.14 and a beta of 1.16. VolitionRX has a fifty-two week low of $0.53 and a fifty-two week high of $15.10.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.41 million. On average, sell-side analysts forecast that VolitionRX will post -2.36 earnings per share for the current fiscal year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.